Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.716 CHF
−470.64 M CHF
13.34 B CHF
1.13 B
About TEVA
Sector
CEO
Richard Francis
Headquarters
Tel Aviv
Website
Founded
1901
FIGI
BBG007FJM261
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
T
TEVA5034099
Teva Pharmaceutical Finance Netherlands III BV 7.125% 31-JAN-2025Yield to maturity
7.40%
Maturity date
Jan 31, 2025
T
TEVA4608603
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028Yield to maturity
7.01%
Maturity date
Mar 1, 2028
T
TEVA5549924
Teva Pharmaceutical Finance Netherlands III BV 8.125% 15-SEP-2031Yield to maturity
6.07%
Maturity date
Sep 15, 2031
T
TEVA5549923
Teva Pharmaceutical Finance Netherlands III BV 7.875% 15-SEP-2029Yield to maturity
5.99%
Maturity date
Sep 15, 2029
T
TEVA4608604
Teva Pharmaceutical Finance Netherlands III BV 6.75% 01-MAR-2028Yield to maturity
5.86%
Maturity date
Mar 1, 2028
T
TEVA4914602
Teva Pharmaceutical Finance Netherlands III BV 7.125% 31-JAN-2025Yield to maturity
5.84%
Maturity date
Jan 31, 2025
T
XS219821395
TEVA PHARM FINANCE NL II 6% GTD SNR NTS 31/01/2025 EUR100000Yield to maturity
5.83%
Maturity date
Jan 31, 2025
T
TEVA5295245
Teva Pharmaceutical Finance Netherlands III BV 5.125% 09-MAY-2029Yield to maturity
5.81%
Maturity date
May 9, 2029
T
TEVA5295244
Teva Pharmaceutical Finance Netherlands III BV 4.75% 09-MAY-2027Yield to maturity
5.78%
Maturity date
May 9, 2027
Explore more bonds